The increasingly popular class of GLP-1 receptor agonist and GIP combined medications, including tirzepatide, semaglutide, and the relatively introduced retatrutide, represent promising progress in the https://semaglutide638924.thezenweb.com/retatrutide-the-comparative-review-82671233